Article Text

other Versions

PDF
Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomized studies of osteoarthritis patients
  1. JY Reginster
  1. Polycliniques Universitaires, Belgium
    1. K Malmstrom
    1. Merck & Co., Inc., United States
      1. A Mehta
      1. Merck & Co., Inc., United States
        1. G Bergman
        1. Merck & Co., Inc., United States
          1. A T Ko
          1. Merck & Co., Inc., United States
            1. S P Curtis (sean_curtis{at}merck.com)
            1. Merck & Co., Inc., United States
              1. A S Reicin
              1. Merck & Co., Inc., United States

                Abstract

                Objectives: To assess the efficacy and safety of etoricoxib 60 mg once daily and naproxen 500 mg twice daily over a 138-week treatment period in patients with osteoarthritis (OA).

                Methods: Two 1-year randomized, double-blind, parallel-group 2-part base studies (Part I 12 weeks; Part II 40 weeks), followed by an 86-week extension, in OA (hip or knee) patients were conducted at 80 clinical centers (19 countries). The studies had identical designs. Patients taking placebo in Part I received etoricoxib or naproxen (1:1 ratio) in Part II and the Extension; patients taking etoricoxib or naproxen in Part I remained on the same treatment throughout the entire length of the studies. Co-primary efficacy endpoints were Patient Global Assessment of Disease Status, and WOMAC questionnaire Pain Subscale and Physical Function Subscale (100mm VAS). Efficacy over 138-weeks was assessed by graphical analysis. Safety was assessed by observation of adverse experiences and laboratory and physical evaluations.

                Results: There were 997 patients who entered (615 completed) the Base studies. Of these patients, 463 patients entered the Extensions. A total of 161 and 151 patients in the etoricoxib and naproxen groups, respectively, completed 138-treatment weeks. Etoricoxib and naproxen showed similar efficacy throughout the 138 weeks of therapy. For etoricoxib and naproxen, respectively, WOMAC Pain assessments were: 67 and 67 mm (baseline); 28 and 29 mm (1-year), and 34 and 33mm (138- weeks). Results for the other efficacy endpoints were similar to those seen with the WOMAC Pain assessments. Both etoricoxib and naproxen were generally well tolerated.

                Conclusion: Both etoricoxib and naproxen demonstrated long-term clinical efficacy for the treatment of OA. Etoricoxib and naproxen were generally well tolerated.

                • COX-2 selective inhibitors
                • NSAIDs
                • etoricoxib
                • naproxen
                • osteoarthritis

                Statistics from Altmetric.com

                Request permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.